LIDOCAINE HYDROCHLORIDE | A080407 | WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Foley & Lardner, LLP FDA-2020-P-1252 · 7 docket documents Foley & Lardner LLP filed an ANDA Suitability Petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that FDA determine a 2 mL fill vial formulation of Lidocaine Hydrochloride Injection USP 10 mg/mL is suitable for ANDA submission, with the formulation being quant | Suitability | 2020-04-07 | Withdrawn | Foley & Lardner, LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0878
per ml
Lowest NADAC/Unit
$0.0700
per ml
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00143957510LIDOCAINE HCL 2% VIAL | $0.0878 | ML | Generic | — | 2026-06-17 |
| 00143957710LIDOCAINE HCL 1% VIAL | $0.0700 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.